A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer¿s Disease Therapy in Patients with Moderate Severity Alzheimer¿s Disease

Project Details

StatusFinished
Effective start/end date25/10/13 → 31/03/19

Funding

  • Hoffmann-La Roche Inc.: $7,994.00

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development